MAPT and Alzheimer disease: TRx0237 is a second-generation inhibitor of tau protein aggregation that underwent Phase III clinical trials to assess the safety and effectiveness of TRx0237 at doses of 16 mg/day and 8 mg/day in the treatment of individuals with AD.